An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

被引：0
|
作者：
Lian-sheng Cheng
Min Zhu
Yan Gao
Wen-ting Liu
Wu Yin
Pengfei Zhou
Zhongliang Zhu
Liwen Niu
Xiaoli Zeng
Dayan Zhang
Qing Fang
Fengrong Wang
Qun Zhao
Yan Zhang
Guodong Shen
机构：
[1] University of Science and Technology of China,Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine
[2] Hefei HankeMab Biotechnology Limited,Anhui Province Key Laboratory of Gene Engineering Pharmaceutical, Biomedicine Technology Innovation Center of Hefei
[3] Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy,School of Life Sciences, Division of Life Sciences and Medicine
[4] Anhui Anke Biotechnology (Group) Co.,School of Health Service Management
[5] Ltd.,undefined
[6] University of Science and Technology of China,undefined
[7] Anhui Medical University,undefined
来源：
Cellular & Molecular Biology Letters | / 28卷
关键词：
Colorectal cancer; Cancer immunotherapy; 4-1BB/CD137; PD-1/PD-L1; Immune checkpoint inhibitor; Antitumor immunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The PD-L1 and OX40 bispecific antibody IBI327 induces immune activation and improves cancer immunotherapy
    Chen, Bingliang
    Kuang, Zhihui
    Li, Yiming
    Zhou, Shuaixiang
    Wu, Zhihai
    Wu, Min
    Yu, Michael
    Liu, Junjian
    CANCER RESEARCH, 2020, 80 (16)
  • [42] Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma
    Zheng, Zhong
    Wang, Jian-Biao
    Sun, Rui
    Wang, Nan
    Weng, Xiang-Qin
    Xu, Tian-Yuan
    Fu, Di
    Feng, Yan
    Xu, Peng-Peng
    Cheng, Shu
    Wang, Li
    Zhao, Yan
    Qu, Bin
    Huang, Chuan-Xin
    Zhao, Wei-Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [43] An Fc-inert PD-L1x4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schoedel, Kristina B.
    Burm, Saskia M.
    Toker, Aras
    Salcedo, Theodora W.
    Verzijl, Dennis
    Eisel, David
    Grunwitz, Christian
    Kranz, Lena M.
    Vormehr, Mathias
    Satijn, David P. E.
    Diken, Mustafa
    Kreiter, Sebastian
    Sasser, Kate
    Ahmadi, Tahamtan
    Tuereci, Oezlem
    Breij, Esther C. W.
    Jure-Kunkel, Maria
    Sahin, Ugur
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [44] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy.
    Chaudhary, Amit K.
    Shi, Jiadong
    Cai, Wenyan
    Wang, Bo
    Zaman, Mohd S.
    Huang, Cai
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Dong, Jianbo
    Liu, Yue
    CANCER RESEARCH, 2021, 81 (13)
  • [45] DUOBODY®-PD-L1x4-1BB (GEN1046) INDUCES SUPERIOR IMMUNE-CELL ACTIVATION, CYTOKINE PRODUCTION AND CYTOTOXICITY BY COMBINING PD-L1 BLOCKADE WITH CONDITIONAL 4-1BB CO-STIMULATION
    Muik, Alexander
    Altintas, Isil
    Kosoff, Rachelle
    Gieseke, Friederike
    Schoedel, Kristina
    Salcedo, Theodora
    Burm, Saskia
    Toker, Aras
    Kranz, Lena
    Vormehr, Mathias
    Eisel, David
    Fereshteh, Mark
    Tuereci, Oezlem
    Breij, Esther
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A338 - A339
  • [46] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Li, Hua-ying
    Chen, Yi-li
    Deng, Xiang-nan
    Li, Huan-huan
    Tan, Jie
    Liu, Guo-jian
    Zheng, Yu-juan
    Pei, Min
    Peng, Kai-ting
    Yue, Li-li
    Chen, Xiao-jia
    Liu, Yu
    Zhao, Yong-shan
    Wang, Chun-he
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (11) : 2322 - 2330
  • [47] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Hua-ying Li
    Yi-li Chen
    Xiang-nan Deng
    Huan-huan Li
    Jie Tan
    Guo-jian Liu
    Yu-juan Zheng
    Min Pei
    Kai-ting Peng
    Li-li Yue
    Xiao-jia Chen
    Yu Liu
    Yong-shan Zhao
    Chun-he Wang
    Acta Pharmacologica Sinica, 2023, 44 : 2322 - 2330
  • [48] A bispecific antibody targeting CLDN18.2 and 4-1BB induces potent anti-tumor efficacy with an extraordinary safety profile
    Chen, Junying
    Huang, Weifeng
    Liang, Zhiquan
    Miao, Xiaoniu
    Peng, Shaogang
    Wang, Chao
    Dong, Tiantian
    Tsun, Andy
    Luo, Yi
    CANCER RESEARCH, 2022, 82 (12)
  • [49] Targeting of 4-1BB by monoclonal antibody, PF-05082566, enhances T cell function and promotes antitumor activity
    Fisher, Timothy S.
    Kamperschroer, Cris
    Oliphant, Theodore
    Love, Victoria A.
    Lira, Paul D.
    Doyonnas, Regis
    Bergqvist, Simon
    Baxi, Sangita
    Rohner, Allison
    Shen, Amy C.
    Huang, Chunli
    Sokolowski, Sharon
    Sharp, Leslie L.
    CANCER RESEARCH, 2012, 72
  • [50] A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC
    Wang, Lili
    Zheng, Junheng
    Tan, Zhihao
    Zhang, Yan
    Wang, Hua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 138
12345